Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Author:

Tap William D,Jones Robin L,Van Tine Brian A,Chmielowski Bartosz,Elias Anthony D,Adkins Douglas,Agulnik Mark,Cooney Matthew M,Livingston Michael B,Pennock Gregory,Hameed Meera R,Shah Gaurav D,Qin Amy,Shahir Ashwin,Cronier Damien M,Ilaria Robert,Conti Ilaria,Cosaert Jan,Schwartz Gary K

Funder

Eli Lilly and Company

Imclone

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Sarcoma immunotherapy: past approaches and future directions;D'Angelo;Sarcoma,2014

2. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systemic review;Sharma;BMC Cancer,2013

3. Management of soft-tissue sarcomas: an overview and update;Singer;Lancet Oncol,2000

4. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic softtissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

5. PICASSO 3: a phase 3 international randomized double blind placebo-controlled study of doxorubicin plus palifosfamide vs. doxorubicin plus placebo for patients in first-line for metastatic soft tissue sarcoma;Ryan;Eur J Cancer,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3